TherapeuticsMD (TXMD) Cash from Financing Activities (2011 - 2023)

TherapeuticsMD (TXMD) has reported Cash from Financing Activities for 13 consecutive years, with $2.0 million the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Cash from Financing Activities rose 101.79% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2023 stood at -$108.2 million (up 54.0% YoY), and the FY2023 full-year result was $3.2 million, up 101.34% from the prior year.
• Cash from Financing Activities climbed to $2.0 million in Q4 2023 per TXMD's latest filing, from -$1000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $111.7 million in Q2 2019 and bottomed at -$120.0 million in Q2 2022.
• Historically, Cash from Financing Activities has averaged $9.2 million across 5 years, with a median of $890500.0 in 2021.
• The sharpest annual moves came in 2020 and 2022: Cash from Financing Activities surged 48669.82% in 2020, then plunged 28137.38% in 2022.
• Over 5 years, Cash from Financing Activities stood at $77.0 million in 2019, then plunged by 58.84% to $31.7 million in 2020, then sank by 95.73% to $1.4 million in 2021, then sank by 8373.84% to -$111.9 million in 2022, then surged by 101.79% to $2.0 million in 2023.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.0 million, -$1000.0, and -$111.9 million for Q4 2023, Q3 2023, and Q4 2022 respectively.